HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases.

AbstractBACKGROUND:
Nonoxynol 9 is a proved spermicide, but whether it is also a microbicide is uncertain. A truly effective vaginal microbicide would reduce the susceptibility of women to sexually transmitted diseases, including infection with the human immunodeficiency virus (HIV).
METHODS:
We enrolled 1292 HIV-negative female sex workers in Cameroon and enrolled them in a double-blind, placebo-controlled study in which the participants were randomly assigned to use either a film containing 70 mg of nonoxynol 9 or a placebo film, inserted into the vagina before intercourse. All of the women were provided with latex condoms and were instructed to have their male sexual partners use them. At monthly follow-up visits, we examined the women with a colposcope for genital lesions, tested endocervical specimens for gonorrhea and chlamydia infection with DNA probes, tested for HIV infection, and treated the women for curable sexually transmitted diseases.
RESULTS:
The rates of HIV infection (cases per 100 woman-years) were 6.7 in the nonoxynol 9 group and 6.6 in the placebo group (rate ratio, 1.0; 95 percent confidence interval, 0.7 to 1.5). The rates of genital lesions were 42.2 cases per 100 woman-years in the nonoxynol 9 group and 33.5 in the placebo group (rate ratio, 1.3; 95 percent confidence interval, 1.0 to 1.6). The rates of gonorrhea were 33.3 and 31.1 cases per 100 woman-years in the nonoxynol 9 and placebo groups, respectively (rate ratio, 1.1; 95 percent confidence interval, 0.8 to 1.4). The corresponding rates of chlamydia infection in the nonoxynol 9 group and the placebo group were 20.6 and 22.2 per 100 woman-years (rate ratio, 0.9; 95 percent confidence interval, 0.7 to 1.3). The women reported that condoms were used during 90 percent of sexual acts.
CONCLUSIONS:
The use of a nonoxynol 9 vaginal film did not reduce the rate of new HIV, gonorrhea, or chlamydia infection in this group of sex workers who used condoms and received treatment for sexually transmitted diseases.
AuthorsR E Roddy, L Zekeng, K A Ryan, U Tamoufé, S S Weir, E L Wong
JournalThe New England journal of medicine (N Engl J Med) Vol. 339 Issue 8 Pg. 504-10 (Aug 20 1998) ISSN: 0028-4793 [Print] United States
PMID9709043 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anti-Infective Agents
  • Spermatocidal Agents
  • Nonoxynol
Topics
  • Adult
  • Anti-Infective Agents (therapeutic use)
  • Chlamydia Infections (epidemiology, prevention & control)
  • Condoms
  • Confounding Factors, Epidemiologic
  • Double-Blind Method
  • Female
  • Genital Diseases, Female (epidemiology)
  • Gonorrhea (epidemiology, prevention & control)
  • HIV Infections (epidemiology, prevention & control)
  • Humans
  • Male
  • Nonoxynol (therapeutic use)
  • Proportional Hazards Models
  • Sex Work
  • Sexually Transmitted Diseases (diagnosis, prevention & control)
  • Spermatocidal Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: